<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="of Tropical Medicine1687-96861687-9694Hindawi pmcid: 7368942 doi: 10.1155/2020/2071325 : Research Article" exact="Reduced" post="Duration of Postchikungunya Musculoskeletal Pain in Rheumatological Patients Treated"/>
 <result pre="any medium, provided the original work is properly cited. Abstract" exact="Chikungunya fever" post="(CHIK) has caused important epidemic outbreaks in the Americas,"/>
 <result pre="the Americas, with musculoskeletal involvement being the main manifestation, causing" exact="chronic" post="symptoms in half of the affected patients. This study"/>
 <result pre="study was performed to evaluate the clinical course of the" exact="infection" post="in 168 patients with autoimmune inflammatory disease using biological"/>
 <result pre="the clinical course of the infection in 168 patients with" exact="autoimmune" post="inflammatory disease using biological disease-modifying antirheumatic drugs (bDMARDs), comparing"/>
 <result pre="course of the infection in 168 patients with autoimmune inflammatory" exact="disease" post="using biological disease-modifying antirheumatic drugs (bDMARDs), comparing this group"/>
 <result pre="those with positive serology, 32 (76%) and 14 (93%) were" exact="symptomatic" post="among subjects in the bDMARD and control groups, respectively"/>
 <result pre="users of anti-TNF. This study found that patients affected by" exact="chikungunya" post="fever using bDMARDs did not present severe forms or"/>
 <result pre="bDMARDs did not present severe forms or complications in the" exact="acute" post="phase of the disease, and patients using anti-TNF biologicals"/>
 <result pre="of the disease, and patients using anti-TNF biologicals had a" exact="lower" post="frequency of chronic joint symptoms than the household controls."/>
 <result pre="and patients using anti-TNF biologicals had a lower frequency of" exact="chronic" post="joint symptoms than the household controls. This favorable outcome"/>
 <result pre="reduction in the inflammatory response and joint damage. 1. Introduction" exact="Chikungunya fever" post="(CHIK) is a mosquito-borne disease, caused by an alphavirus"/>
 <result pre="an epidemic that occurred in 2017 [1, 2]. Clinically, the" exact="disease" post="is characterized by fever and joint pain that is"/>
 <result pre="fever and joint pain that is generally disabling in the" exact="acute" post="phase and may last from months to years, with"/>
 <result pre="from months to years, with the potential to evolve into" exact="chronic" post="musculoskeletal symptoms in approximately 30â€&quot;40% of cases [3]. In"/>
 <result pre="30â€&quot;40% of cases [3]. In addition, the spectrum of the" exact="disease" post="includes severe and atypical forms, with involvement of the"/>
 <result pre="In addition, the spectrum of the disease includes severe and" exact="atypical" post="forms, with involvement of the central and peripheral nervous"/>
 <result pre="severe and atypical forms, with involvement of the central and" exact="peripheral" post="nervous system, heart, kidneys, lungs, liver, and circulatory system"/>
 <result pre="outbreaks, there is a concern about the intensity of the" exact="disease" post="in the acute phase, which may cause incapacity, and"/>
 <result pre="a concern about the intensity of the disease in the" exact="acute" post="phase, which may cause incapacity, and the risk of"/>
 <result pre="complications in users of immunosuppressive drugs, especially patients with rheumatological" exact="disease" post="who already have joint involvement [8, 9]. The use"/>
 <result pre="immunosuppressive effects, predisposing the users to an increased risk of" exact="infections" post="and their complications by viruses such as cytomegalovirus (CMV),"/>
 <result pre="and their complications by viruses such as cytomegalovirus (CMV), varicella" exact="zoster" post="virus, Epstein-Barr virus, hepatitis B virus, and influenza virus"/>
 <result pre="complications by viruses such as cytomegalovirus (CMV), varicella zoster virus," exact="Epstein-Barr virus, hepatitis" post="B virus, and influenza virus [8â€&quot;10]. On the other"/>
 <result pre="viruses such as cytomegalovirus (CMV), varicella zoster virus, Epstein-Barr virus," exact="hepatitis" post="B virus, and influenza virus [8â€&quot;10]. On the other"/>
 <result pre="cytokines, can reduce the inflammatory process in tissues induced by" exact="viral infection," post="and may have benefits in the outcome of some"/>
 <result pre="benefits in the outcome of some diseases that have a" exact="chronic" post="pattern, such as chikungunya fever [11â€&quot;13]. Thus, based on"/>
 <result pre="of some diseases that have a chronic pattern, such as" exact="chikungunya" post="fever [11â€&quot;13]. Thus, based on the above information and"/>
 <result pre="epidemics caused by CHIKV, it is necessary to assess the" exact="disease" post="pattern in users of these immunosuppressive drugs, defining the"/>
 <result pre="the clinical pattern and evolution of CHIK in patients with" exact="chronic" post="inflammatory arthropathy using bDMARDs and to verify the frequency"/>
 <result pre="pattern and evolution of CHIK in patients with chronic inflammatory" exact="arthropathy" post="using bDMARDs and to verify the frequency of asymptomatic"/>
 <result pre="arthropathy using bDMARDs and to verify the frequency of asymptomatic" exact="CHIKV infection" post="compared with that of healthy household contacts. 2. Materials"/>
 <result pre="using bDMARDs and to verify the frequency of asymptomatic CHIKV" exact="infection" post="compared with that of healthy household contacts. 2. Materials"/>
 <result pre="conducted a retrospective cross-sectional study that included patients diagnosed with" exact="chronic" post="inflammatory rheumatologic disease using bDMARDs who were treated at"/>
 <result pre="cross-sectional study that included patients diagnosed with chronic inflammatory rheumatologic" exact="disease" post="using bDMARDs who were treated at the Rheumatology Service"/>
 <result pre="were patients older than 18 years who were diagnosed with" exact="chronic" post="inflammatory arthropathy (rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis)"/>
 <result pre="older than 18 years who were diagnosed with chronic inflammatory" exact="arthropathy" post="(rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis) and who"/>
 <result pre="years who were diagnosed with chronic inflammatory arthropathy (rheumatoid arthritis," exact="ankylosing spondylitis," post="or psoriatic arthritis) and who used bDMARD. For the"/>
 <result pre="group (control), we selected people with no diagnosis of inflammatory" exact="disease" post="or use of immunosuppressants who lived in the same"/>
 <result pre="and controls to collect clinical information about suggestive symptoms of" exact="CHIKV infection" post="between December 2016 and May 2017, the period of"/>
 <result pre="controls to collect clinical information about suggestive symptoms of CHIKV" exact="infection" post="between December 2016 and May 2017, the period of"/>
 <result pre="with a history of sudden onset fever &amp;gt;38.5Â°C and severe" exact="acute" post="onset arthralgia or arthritis not explained by other conditions"/>
 <result pre="sudden onset fever &amp;gt;38.5Â°C and severe acute onset arthralgia or" exact="arthritis" post="not explained by other conditions were considered to be"/>
 <result pre="bDMARD in use, duration of symptoms suggestive of CHIK after" exact="acute" post="infection, comorbidities, smoking history, intensity of pain in the"/>
 <result pre="acute infection, comorbidities, smoking history, intensity of pain in the" exact="acute" post="and chronic phases by visual analog scale (VAS) from"/>
 <result pre="comorbidities, smoking history, intensity of pain in the acute and" exact="chronic" post="phases by visual analog scale (VAS) from 0 to"/>
 <result pre="intensity of pain in the acute and chronic phases by" exact="visual" post="analog scale (VAS) from 0 to 10, pattern of"/>
 <result pre="joint involvement (mono-, oligo-, or polyarticular), and possible complications or" exact="atypical" post="manifestations in the acute phase. Patients who met the"/>
 <result pre="or polyarticular), and possible complications or atypical manifestations in the" exact="acute" post="phase. Patients who met the clinical criteria of suspected"/>
 <result pre="Patients who met the clinical criteria of suspected cases of" exact="acute" post="CHIK with positive IgG serology and a history of"/>
 <result pre="serology and a history of persistent musculoskeletal symptoms of the" exact="acute" post="phase for a period longer than three months were"/>
 <result pre="period longer than three months were considered as cases with" exact="chronic" post="involvement. Regarding the clinical pattern of musculoskeletal pain, the"/>
 <result pre="no period of symptom improvement or arthralgia remission after the" exact="acute" post="episode of chikungunya until the interview or complete regression"/>
 <result pre="symptom improvement or arthralgia remission after the acute episode of" exact="chikungunya" post="until the interview or complete regression of the condition"/>
 <result pre="after the acute episode of chikungunya until the interview or" exact="complete" post="regression of the condition were considered to exhibit the"/>
 <result pre="by exacerbations with the same characteristics as those of the" exact="acute" post="phase, between the period from the onset of the"/>
 <result pre="from the onset of the condition until the interview or" exact="complete" post="regression. Five milliliters of blood was collected and analyzed"/>
 <result pre="the absolute risk reduction (AAR), to compare the results between" exact="symptomatic" post="patients with and without bDMARD. The confidence interval was"/>
 <result pre="age of 50.15 years (Â±13.92) and 48.47 (Â±16.85), respectively (p=0.314)." exact="Female" post="sex corresponded to 67% of the cases in the"/>
 <result pre="57% of the control group (p=0.001). Regarding the group having" exact="chronic" post="inflammatory arthropathy and using bDMARDs, 94 (56%) subjects had"/>
 <result pre="the control group (p=0.001). Regarding the group having chronic inflammatory" exact="arthropathy" post="and using bDMARDs, 94 (56%) subjects had a diagnosis"/>
 <result pre="and using bDMARDs, 94 (56%) subjects had a diagnosis of" exact="rheumatoid arthritis," post="and the most frequent class of immunobiological used was"/>
 <result pre="1). 3.2. Symptoms of CHIKV and Seropositivity Suggestive symptoms of" exact="CHIKV infection" post="were reported by 51/168 (30%) of the patients in"/>
 <result pre="3.2. Symptoms of CHIKV and Seropositivity Suggestive symptoms of CHIKV" exact="infection" post="were reported by 51/168 (30%) of the patients in"/>
 <result pre="most frequent was joint pain (98.6%), followed by fever (82%)," exact="arthritis" post="(75%), and myalgia (75%). No significant difference was observed"/>
 <result pre="symptoms between the two groups. There was no difference in" exact="acute" post="pain intensity between the two groups (VAS 8.78 in"/>
 <result pre="group; 9.04 in the control group; p=0.615) or in the" exact="chronic" post="phase (VAS 5.23 in the bDMARD group; 5.08 in"/>
 <result pre="that the use of bDMARDs was not associated with severe," exact="atypical" post="forms and complications of chikungunya fever, while it was"/>
 <result pre="was not associated with severe, atypical forms and complications of" exact="chikungunya" post="fever, while it was associated with a shorter duration"/>
 <result pre="use of anti-TNF biologicals, and a larger number of asymptomatic" exact="infection" post="cases, although without statistical significance. A few published studies"/>
 <result pre="although with different methodologies [15, 16]. Experimental models of alphavirus-induced" exact="arthritis" post="suggest that CHIK pathogenesis is the result of a"/>
 <result pre="a combination of direct cellular and tissue damage caused by" exact="viral" post="replication and mainly by activation of the indirect immune"/>
 <result pre="and the presence of symptoms at different stages of the" exact="disease" post="[19]. Since TNF is one of the elements involved"/>
 <result pre="could potentially slow the inflammatory process in tissues in the" exact="acute" post="phase of CHIKV infection. Our finding of this more"/>
 <result pre="the inflammatory process in tissues in the acute phase of" exact="CHIKV infection." post="Our finding of this more favorable clinical evolution in"/>
 <result pre="of inflammation by blocking cytokines involved in the pathophysiology of" exact="chronic" post="joint injury. The seroprevalence of anti-CHIKV IgG observed in"/>
 <result pre="suggesting that despite immunosuppression, there was no increased risk of" exact="symptomatic" post="infections. Another relevant finding was that most symptomatic bDMARD-using"/>
 <result pre="risk of symptomatic infections. Another relevant finding was that most" exact="symptomatic" post="bDMARD-using patients had a shorter CHIK-related symptom duration than"/>
 <result pre="(Ross River virus), in which etanercept was applied in the" exact="acute" post="phase, showed a higher viral load and higher recruitment"/>
 <result pre="etanercept was applied in the acute phase, showed a higher" exact="viral" post="load and higher recruitment of inflammatory cells and tissue"/>
 <result pre="suggesting that the use of anti-TNF biologicals could aggravate the" exact="disease" post="[22]. However, this result is not reproduced in clinical"/>
 <result pre="clinical practice, although the use of anti-TNF biologicals in the" exact="acute" post="phase has not been evaluated exclusively. Two studies in"/>
 <result pre="Two studies in the literature refer to the pattern of" exact="CHIKV infection" post="in biological users and do not show a more"/>
 <result pre="studies in the literature refer to the pattern of CHIKV" exact="infection" post="in biological users and do not show a more"/>
 <result pre="in biological users and do not show a more severe" exact="joint disease" post="in this group of patients [15, 16]. Rosario V."/>
 <result pre="biological users and do not show a more severe joint" exact="disease" post="in this group of patients [15, 16]. Rosario V."/>
 <result pre="Rosario V. et al. described 53 cases of patients with" exact="rheumatoid arthritis" post="(RA) using different immunobiologicals either alone or associated with"/>
 <result pre="V. et al. described 53 cases of patients with rheumatoid" exact="arthritis" post="(RA) using different immunobiologicals either alone or associated with"/>
 <result pre="disease-modifying drugs (methotrexate, leflunomide, sulfasalazine, and hydroxychloroquine), with polyarthralgia and" exact="arthritis" post="occurring in 96.2% and 47% of the cases, without"/>
 <result pre="without differences when compared to a group of patients with" exact="chikungunya" post="without a history of previous arthropathy; however, the duration"/>
 <result pre="beneficial effect of cytokine blockade has been reported in other" exact="viral" post="infections, such as dengue, Zika, influenza, and, most recently,"/>
 <result pre="such as dengue, Zika, influenza, and, most recently, in coronavirus" exact="infections" post="due to the pandemic of COVID-19 [11â€&quot;13, 23â€&quot;25]. An"/>
 <result pre="study with the BALB/c mouse strain infected with dengue virus" exact="type 2" post="identified elevated levels of TNF-Î± within the first 24"/>
 <result pre="been shown in this study, the current recommendation of the" exact="Brazilian" post="Society of Rheumatology for patients using bDMARDs with clinical-epidemiological"/>
 <result pre="patients using bDMARDs with clinical-epidemiological or laboratory diagnosis of arbovirus" exact="infection" post="is to suspend biological therapy until recovery from the"/>
 <result pre="infection is to suspend biological therapy until recovery from the" exact="acute" post="phase of the disease [21]. The limitations of this"/>
 <result pre="biological therapy until recovery from the acute phase of the" exact="disease" post="[21]. The limitations of this study include the retrospective"/>
 <result pre="after the period of the epidemic and the symptoms of" exact="chikungunya" post="are intense and characteristic, this tendency is likely to"/>
 <result pre="the significant difference in the number of cases with subclinical" exact="infection" post="between the two groups. 5. Conclusion In patients with"/>
 <result pre="infection between the two groups. 5. Conclusion In patients with" exact="chronic" post="inflammatory arthropathy, the use of bDMARDs does not seem"/>
 <result pre="outcomes in patients infected by CHIKV, and we observed a" exact="lower" post="frequency of chronic joint symptoms that may be related"/>
 <result pre="infected by CHIKV, and we observed a lower frequency of" exact="chronic" post="joint symptoms that may be related to possible TNF"/>
 <result pre="be related to possible TNF blockade in the presence of" exact="CHIKV infection." post="In this study, patients with chronic inflammatory arthropathy using"/>
 <result pre="the presence of CHIKV infection. In this study, patients with" exact="chronic" post="inflammatory arthropathy using bDMARDs did not present severe forms"/>
 <result pre="of CHIKV infection. In this study, patients with chronic inflammatory" exact="arthropathy" post="using bDMARDs did not present severe forms of CHIK"/>
 <result pre="present severe forms of CHIK or complications related to the" exact="acute" post="disease. A lower frequency of chronicity of joint symptoms"/>
 <result pre="of CHIK or complications related to the acute disease. A" exact="lower" post="frequency of chronicity of joint symptoms was observed, compared"/>
 <result pre="not significantly interfere with the immune response mechanisms against these" exact="viral" post="infections, facilitate viral replication, or play a role in"/>
 <result pre="with the immune response mechanisms against these viral infections, facilitate" exact="viral" post="replication, or play a role in the worsening of"/>
 <result pre="studies are needed to better assess the behavior of this" exact="disease" post="in biological therapy users, helping define the risks and"/>
 <result pre="the risks and benefits and guide the therapeutic approach to" exact="chikungunya" post="infection. Data Availability The data used to support the"/>
 <result pre="bDMARDs are not associated with worsened outcomes in patients with" exact="CHIKV infection." post="Anti-TNF biological use may reduce symptom duration in chikungunya"/>
 <result pre="CHIKV infection. Anti-TNF biological use may reduce symptom duration in" exact="chikungunya" post="fever patients. Disclosure The partial results of this study"/>
 <result pre="may reduce symptom duration in chikungunya fever patients. Disclosure The" exact="partial" post="results of this study were presented at the â€œ36Â°"/>
 <result pre="that they have no conflicts of interest. References 1collab: Pan" exact="American" post="Health OrganizationNew Cases of Chikungunya in the Americas, 2013â€&quot;20172020Washington,"/>
 <result pre="OrganizationNew Cases of Chikungunya in the Americas, 2013â€&quot;20172020Washington, DC, USAPan" exact="American" post="Health Organizationhttps://www.paho.org/hq/dmdocuments/2017/2017-jul-7-phe-CHIKV-cases-ew-27.pdf 2Brazil, Ministry of Healthâ€&quot;Secretariat of Health Surveillance"/>
 <result pre="Health Surveillance Epidemiological Bulletin: Monitoring of Cases of Dengue, Chikungunya" exact="Fever" post="and Fever by the Zika Virus Until the Epidemiological"/>
 <result pre="Epidemiological Bulletin: Monitoring of Cases of Dengue, Chikungunya Fever and" exact="Fever" post="by the Zika Virus Until the Epidemiological Week 48"/>
 <result pre="48 of 2017, BrasÃ­lia, 2017, https://www.saude.gov.br/images/pdf/2017/dezembro/26/BE-2017-043-Boletim.pdf 3Rodriguez-MoralesA. J.Gil-RestrepoA. F.RamÃ­rez-JaramilloV.et al.Post-chikungunya" exact="chronic" post="inflammatory rheumatism: results from a retrospective follow-up study of"/>
 <result pre="inflammatory rheumatism: results from a retrospective follow-up study of 283" exact="adult" post="and child cases in La Virginia, Risaralda, ColombiaF1000Research20165p. 36010.12688/f1000research.8235.2"/>
 <result pre="Virginia, Risaralda, ColombiaF1000Research20165p. 36010.12688/f1000research.8235.2 4BonifayT.PrinceC.NeyraC.et al.Atypical and severe manifestations of" exact="chikungunya" post="virus infection in French Guiana: a hospital-based studyPLoS One2018131210.1371/journal.pone.0207406"/>
 <result pre="Risaralda, ColombiaF1000Research20165p. 36010.12688/f1000research.8235.2 4BonifayT.PrinceC.NeyraC.et al.Atypical and severe manifestations of chikungunya" exact="virus infection" post="in French Guiana: a hospital-based studyPLoS One2018131210.1371/journal.pone.0207406 5Antunes de"/>
 <result pre="ColombiaF1000Research20165p. 36010.12688/f1000research.8235.2 4BonifayT.PrinceC.NeyraC.et al.Atypical and severe manifestations of chikungunya virus" exact="infection" post="in French Guiana: a hospital-based studyPLoS One2018131210.1371/journal.pone.0207406 5Antunes de"/>
 <result pre="in BrazilRevista da Sociedade Brasileira de Medicina Tropical201750558558910.1590/0037-8682-0479-201629160503 6EconomopoulouA.DominguezM.HelynckB.et al.Atypical" exact="chikungunya" post="virus infections: clinical manifestations, mortality and risk factors for"/>
 <result pre="virus infections: clinical manifestations, mortality and risk factors for severe" exact="disease" post="during the 2005-2006 outbreak on rÃ©unionEpidemiology and Infection2009137453454110.1017/S095026880800116718694529 7RenaultP.de"/>
 <result pre="on rÃ©unionEpidemiology and Infection2009137453454110.1017/S095026880800116718694529 7RenaultP.de ValkH.BalleydierE.et al.A major epidemic of" exact="chikungunya" post="virus infection on rÃ©union island, France, 2005-2006The American Journal"/>
 <result pre="rÃ©unionEpidemiology and Infection2009137453454110.1017/S095026880800116718694529 7RenaultP.de ValkH.BalleydierE.et al.A major epidemic of chikungunya" exact="virus infection" post="on rÃ©union island, France, 2005-2006The American Journal of Tropical"/>
 <result pre="and Infection2009137453454110.1017/S095026880800116718694529 7RenaultP.de ValkH.BalleydierE.et al.A major epidemic of chikungunya virus" exact="infection" post="on rÃ©union island, France, 2005-2006The American Journal of Tropical"/>
 <result pre="epidemic of chikungunya virus infection on rÃ©union island, France, 2005-2006The" exact="American" post="Journal of Tropical Medicine and Hygiene200777472773110.4269/ajtmh.2007.77.72717978079 8RutherfordA. I.SubesingheS.HyrichK. L.GallowayJ."/>
 <result pre="Journal of Tropical Medicine and Hygiene200777472773110.4269/ajtmh.2007.77.72717978079 8RutherfordA. I.SubesingheS.HyrichK. L.GallowayJ. B.Serious" exact="infection" post="across biologic-treated patients with rheumatoid arthritis: results from the"/>
 <result pre="arthritisAnnals of the Rheumatic Diseases201877610.1136/annrheumdis-2017-212825 9FernÃ¡ndez-RuizM.MeijeY.ManuelO.et al.ESCMID study group for" exact="infections" post="in compromised hosts (ESGICH) consensus document on the safety"/>
 <result pre="document on the safety of targeted and biological therapies: an" exact="infectious diseases" post="perspective (introduction)Clinical Microbiology and Infection2018242S2S910.1016/j.cmi.2018.01.02929427801 10BormanZ. A.CÃ´tÃ©-DaigneaultJ.ColombelJ.-F.The risk for"/>
 <result pre="diseases perspective (introduction)Clinical Microbiology and Infection2018242S2S910.1016/j.cmi.2018.01.02929427801 10BormanZ. A.CÃ´tÃ©-DaigneaultJ.ColombelJ.-F.The risk for" exact="opportunistic infections" post="in inflammatory bowel disease with biologics: an updateExpert Review"/>
 <result pre="perspective (introduction)Clinical Microbiology and Infection2018242S2S910.1016/j.cmi.2018.01.02929427801 10BormanZ. A.CÃ´tÃ©-DaigneaultJ.ColombelJ.-F.The risk for opportunistic" exact="infections" post="in inflammatory bowel disease with biologics: an updateExpert Review"/>
 <result pre="Microbiology and Infection2018242S2S910.1016/j.cmi.2018.01.02929427801 10BormanZ. A.CÃ´tÃ©-DaigneaultJ.ColombelJ.-F.The risk for opportunistic infections in" exact="inflammatory bowel disease" post="with biologics: an updateExpert Review of Gastroenterology &amp;amp; Hepatology201812111101110810.1080/17474124.2018.153098330277409"/>
 <result pre="and Infection2018242S2S910.1016/j.cmi.2018.01.02929427801 10BormanZ. A.CÃ´tÃ©-DaigneaultJ.ColombelJ.-F.The risk for opportunistic infections in inflammatory" exact="bowel" post="disease with biologics: an updateExpert Review of Gastroenterology &amp;amp;"/>
 <result pre="Infection2018242S2S910.1016/j.cmi.2018.01.02929427801 10BormanZ. A.CÃ´tÃ©-DaigneaultJ.ColombelJ.-F.The risk for opportunistic infections in inflammatory bowel" exact="disease" post="with biologics: an updateExpert Review of Gastroenterology &amp;amp; Hepatology201812111101110810.1080/17474124.2018.153098330277409"/>
 <result pre="13FigueiredoC. P.Barros-AragÃ£oF. G. Q.NerisR. L. S.et al.Zika virus replicates in" exact="adult" post="human brain tissue and impairs synapses and memory in"/>
 <result pre="G. Q.NerisR. L. S.et al.Zika virus replicates in adult human" exact="brain" post="tissue and impairs synapses and memory in miceNature Communications2019101p."/>
 <result pre="389010.1038/s41467-019-11866-7 14PratC. M.FlusinO.PanellaA.TenebrayB.LanciottiR.Leparc-GoffartI.Evaluation of commercially available serologic diagnostic tests for" exact="chikungunya" post="virusEmerging Infectious Diseases201420122129213210.3201/eid2012.14126925418184 15RosarioV.Munoz-LouisR.ValdezT.et al.Chikungunya infection in the general"/>
 <result pre="M.FlusinO.PanellaA.TenebrayB.LanciottiR.Leparc-GoffartI.Evaluation of commercially available serologic diagnostic tests for chikungunya virusEmerging" exact="Infectious" post="Diseases201420122129213210.3201/eid2012.14126925418184 15RosarioV.Munoz-LouisR.ValdezT.et al.Chikungunya infection in the general population and"/>
 <result pre="serologic diagnostic tests for chikungunya virusEmerging Infectious Diseases201420122129213210.3201/eid2012.14126925418184 15RosarioV.Munoz-LouisR.ValdezT.et al.Chikungunya" exact="infection" post="in the general population and in patients with rheumatoid"/>
 <result pre="al.Chikungunya infection in the general population and in patients with" exact="rheumatoid arthritis" post="on biological therapyClinical Rheumatology20153471285128710.1007/s10067-015-2979-x26017232 16BrunierL.PolomatK.DelignyC.et al.Chikungunya virus infection in"/>
 <result pre="infection in the general population and in patients with rheumatoid" exact="arthritis" post="on biological therapyClinical Rheumatology20153471285128710.1007/s10067-015-2979-x26017232 16BrunierL.PolomatK.DelignyC.et al.Chikungunya virus infection in"/>
 <result pre="patients with rheumatoid arthritis on biological therapyClinical Rheumatology20153471285128710.1007/s10067-015-2979-x26017232 16BrunierL.PolomatK.DelignyC.et al.Chikungunya" exact="virus infection" post="in patients on biotherapiesJoint Bone Spine201683224524610.1016/j.jbspin.2015.08.00426603267 17AssunÃ§Ã£o-MirandaI.Cruz-OliveiraC.Da PoianA. T.Molecular"/>
 <result pre="with rheumatoid arthritis on biological therapyClinical Rheumatology20153471285128710.1007/s10067-015-2979-x26017232 16BrunierL.PolomatK.DelignyC.et al.Chikungunya virus" exact="infection" post="in patients on biotherapiesJoint Bone Spine201683224524610.1016/j.jbspin.2015.08.00426603267 17AssunÃ§Ã£o-MirandaI.Cruz-OliveiraC.Da PoianA. T.Molecular"/>
 <result pre="B.TanabeE. L. L.SantosE. C.et al.Cellular and molecular immune response to" exact="chikungunya" post="virus infectionFrontiers in Cellular and Infection Microbiology20188p. 34510.3389/fcimb.2018.00345 19VenugopalanA.GhorpadeR."/>
 <result pre="molecular immune response to chikungunya virus infectionFrontiers in Cellular and" exact="Infection" post="Microbiology20188p. 34510.3389/fcimb.2018.00345 19VenugopalanA.GhorpadeR. P.ChopraA.Cytokines in acute chikungunyaPLoS One201491010.1371/journal.pone.0111305 20CunhaR."/>
 <result pre="infectionFrontiers in Cellular and Infection Microbiology20188p. 34510.3389/fcimb.2018.00345 19VenugopalanA.GhorpadeR. P.ChopraA.Cytokines in" exact="acute" post="chikungunyaPLoS One201491010.1371/journal.pone.0111305 20CunhaR. V.TrintaK. S.MontalbanoC. A.et al.Seroprevalence of chikungunya"/>
 <result pre="in acute chikungunyaPLoS One201491010.1371/journal.pone.0111305 20CunhaR. V.TrintaK. S.MontalbanoC. A.et al.Seroprevalence of" exact="chikungunya" post="virus in a rural community in BrazilPLoS Neglected Tropical"/>
 <result pre="community in BrazilPLoS Neglected Tropical Diseases201711110.1371/journal.pntd.0005319 21MarquesC.DuarteA.RanzolinA.et al.Recommendations of the" exact="Brazilian" post="society of rheumatology for diagnosis and treatment of chikungunya"/>
 <result pre="the Brazilian society of rheumatology for diagnosis and treatment of" exact="chikungunya" post="fever. Part 1â€&quot;diagnosis and special situationsRevista Brasileira de Reumatologia20175742143710.1016/j.rbre.2017.05.00628751131"/>
 <result pre="S.SuhrbierA.MahalingamS.Disease exacerbation by etanercept in a mouse model of alphaviral" exact="arthritis" post="and myositisArthritis &amp;amp; Rheumatism201163248849110.1002/art.3011221280003 23StebbingJ.PhelanA.GriffinI.et al.COVID-19: combining antiviral and"/>
 <result pre="&amp;amp; Rheumatism201163248849110.1002/art.3011221280003 23StebbingJ.PhelanA.GriffinI.et al.COVID-19: combining antiviral and anti-inflammatory treatmentsThe Lancet" exact="Infectious" post="Diseases202020440040210.1016/S1473-3099(20)30132-832113509 24TobinickE.TNF-Î± inhibition for potential therapeutic modulation of SARS"/>
 <result pre="Medical Research and Opinion2004201394010.1185/03007990312500275714741070 25ShiX.ZhouW.HuangH.et al.Inhibition of the inflammatory cytokine" exact="tumor" post="necrosis factor-alpha with etanercept provides protection against lethal H1N1"/>
 <result pre="necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza" exact="infection" post="in miceCritical Care2013176p. R30110.1186/cc13171 Table 1 Clinical and demographic"/>
 <result pre="1 Clinical and demographic data comparing the group with rheumatologic" exact="disease" post="using bDMARDs and the control group. â€‰ bDMARD (Nâ€‰=â€‰168)"/>
 <result pre="9 (16) 0.359 â€ƒPsoriasis 18 (11) 0 (0) 0.026 â€ƒRespiratory" exact="disease" post="20 (12) 3 (5) 0.405 â€ƒSmoking 6 (4) 7"/>
 <result pre="3 (5) 0.405 â€ƒSmoking 6 (4) 7 (13) 0.002 â€ƒCardiovascular" exact="disease" post="11 (6.5) 5 (9) 0.341 â€ƒRenal disease 4 (2)"/>
 <result pre="(13) 0.002 â€ƒCardiovascular disease 11 (6.5) 5 (9) 0.341 â€ƒRenal" exact="disease" post="4 (2) 2 (4) 0.610 â€ƒInflammatory bowel disease 7"/>
 <result pre="(9) 0.341 â€ƒRenal disease 4 (2) 2 (4) 0.610 â€ƒInflammatory" exact="bowel" post="disease 7 (4) 0 (0) 0.190 Rheumatologic diagnosisâ€&quot;N (%)"/>
 <result pre="0.341 â€ƒRenal disease 4 (2) 2 (4) 0.610 â€ƒInflammatory bowel" exact="disease" post="7 (4) 0 (0) 0.190 Rheumatologic diagnosisâ€&quot;N (%) â€‰"/>
 <result pre="0 (0) 0.190 Rheumatologic diagnosisâ€&quot;N (%) â€‰ â€‰ â€‰ â€ƒRheumatoid" exact="arthritis" post="94 (56) â€&quot; â€&quot; â€ƒAnkylosing spondylitis 44 (26) â€&quot;"/>
 <result pre="â€‰ â€‰ â€‰ â€ƒRheumatoid arthritis 94 (56) â€&quot; â€&quot; â€ƒAnkylosing" exact="spondylitis" post="44 (26) â€&quot; â€&quot; â€ƒPsoriatic arthritis 18 (11) â€&quot;"/>
 <result pre="(56) â€&quot; â€&quot; â€ƒAnkylosing spondylitis 44 (26) â€&quot; â€&quot; â€ƒPsoriatic" exact="arthritis" post="18 (11) â€&quot; â€&quot; â€ƒSpondyloarthritis 8 (5) â€&quot; â€&quot;"/>
 <result pre="8 (5) â€&quot; â€&quot; â€ƒPsoriasis 2 (1) â€&quot; â€&quot; â€ƒUveitis/BehÃ§et" exact="disease" post="2 (1) â€&quot; â€&quot; bDMARDâ€&quot;N (%) 168 (100) â€&quot;"/>
 <result pre="(25) 15 (27) 0.79 â€ƒNegative 126 (75) 41 (73) TNF:" exact="tumor" post="necrosis factor; bDMARD: biological disease-modifying antirheumatic drug. #t-test; âˆ—infliximab,"/>
 <result pre="other bDMARDs. Symptom duration bDMARD N (%) Control N (%)" exact="Total" post="p value (ARR; 95% CI) &amp;lt;3 months 23 (72%)"/>
</results>
